Skip to main content
. 2022 Apr 26;12(5):694. doi: 10.3390/jpm12050694

Figure 3.

Figure 3

Humoral response of IBD patients and healthy controls 6 months after second vaccination. (a) Percentage seroconversion rates (SARS-CoV-2 S-IgG ≥ 50 AU/mL); (b) percentage sVNT inhibition. IBD: inflammatory bowel disease. ** p < 0.01. ns, not significant. Categorical variables were compared using the chi-square test or Fisher’s exact test.